From the FDA Drug Label
The patient or caregiver should stop using when signs and symptoms (e.g., itch, rash and redness) resolve and should be instructed on what actions to take if symptoms recur. If signs and symptoms persist beyond 6 weeks, patients should be re-examined by their health care provider to confirm the diagnosis of atopic dermatitis. The recommended treatment duration for Elidel (pimecrolimus) is until signs and symptoms resolve. If symptoms persist beyond 6 weeks, patients should be re-examined by their health care provider 1.